Figure 2.

The sensitivity of colorectalcancer (CRC) xenograft tumors to FL118 treatment is not associated with the expression level of Top1: The small image insert within each xenograft tumor histogram curve was the expression of Top1 proteins measured using western blots with Top1 antibodies from two independent commercial sources. Individual xenograft tumors were first established from their corresponding CRC cell lines (RKO, LS513, LIM2551, SUN-C1, LS411N, Caco-2, SW837, NCI-H747,) by subcutaneous injection of 2 million cells at the flank area of SCID mice, respectively. Then the established tumors were inoculated into SCID mice at the flank area for testing FL118 sensitivity. FL118 treatment was initiated at the time when the inoculated individual xenograft tumors reached 100-200 mm³ (designated day 0). FL118 was administered with the schedule of weekly × 4 (arrowed) via po (per oral) routes at a dose of 10 mg/kg (MTD: maximum tolerated dose). Individual tumor curves were derived from the mean tumor sizes ± SD from up to five mice. These in vivo experimental studies were performed following the mouse protocol that was approved by the Institutional Animal Care and Use Committee (IACUC) at Roswell Park Cancer Institute. (Data were adapted from our previous publication: Li et al Am J Cancer Res 2017; 7: 370-382).